✨ Free AI Report
Citius Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Citius Pharmaceuticals, Inc.
Company Research

Citius Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on developing first-in-class critical care products. The company has achieved FDA approval for LYMPHIR, a targeted immunotherapy for cutaneous T...

Analyst-debate audio for Citius Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Citius Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Challenged

Cyborg Score thesis

High clinical potential undermined by acute liquidity crisis; execution risk on LYMPHIR launch is substantial given capital...

Read the full analyst-debate transcript →
Industry Biopharmaceutical Development & Critical Care Therapeutics
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Citius Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Citius Pharmaceuticals, Inc. Overview

Pro stress-test →

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on developing first-in-class critical care products. The company has achieved FDA approval for LYMPHIR, a targeted immunotherapy for cutaneous T-cell lymphoma, and maintains a pipeline spanning anti-infectives, oncology, adjunct cancer care, and stem cell therapies.

Strategic Profile

Pro stress-test →

Citius operates through a specialized oncology subsidiary (Citius Oncology) and emphasizes clinically validated solutions for unmet medical needs in critical care. The company is strategically positioning LYMPHIR for market launch while advancing pipeline candidates including Mino-Lok for catheter-related infections and NoveCite for ARDS treatment.

Competitive Landscape

Pro stress-test →

Citius competes in the critical care and oncology therapy space against larger biopharmaceuticals with established commercialization infrastructure. Direct competitors include companies developing cutaneous T-cell lymphoma therapies, anti-infective solutions for hospital-acquired infections, and stem cell therapies, though Citius's first-in-class positioning in specific indications provides differentiation.

Industry Context

Citius Pharmaceuticals, Inc. operates in Biopharmaceutical Development & Critical Care Therapeutics.

Key facts

Founded: 2007 · Headquarters: Cranford, New Jersey, US · Revenue: $0 · Market cap: $8.0M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Citius Pharmaceuticals, Inc..

  • LYMPHIR achieved FDA approval as a targeted immunotherapy for cutaneous T-cell lymphoma, marking the company's first approved product and critical commercial milestone
  • Severe liquidity crisis with only $26K cash as of March 31, 2025, requiring immediate capital raises; company completed $1.735M registered direct offering in April 2025
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2025Q2 2025 results showed $26K cash, $11.5M net loss; secured $1.735M registered direct offering
  • April 2025Completed $1.735 million registered direct offering for capital; raised $6 million through equity issuance
  • +2 moreTrack every material event for Citius Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Citius Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Cutaneous T-cell Lymphoma TherapiesEstablished CTCL treatment portfolios with commercial scale→Anti-infective SolutionsCatheter-lock and anti-infective product developers→Stem Cell TherapiesARDS and critical care stem cell therapies→

Compare Citius Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Citius Pharmaceuticals, Inc. operates in Biopharmaceutical Development & Critical Care Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical Development & Critical Care Therapeutics research →
NEW · MCP server

Ask your AI assistant about Citius Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Citius Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Citius Pharmaceuticals, Inc. do this quarter?”
“Is Citius Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Citius Pharmaceuticals, Inc. do?+
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on developing first-in-class critical care products. The company has achieved FDA approval for LYMPHIR, a targeted immunotherapy for cutaneous T...
What is Citius Pharmaceuticals, Inc.'s Cyborg Score?+
Citius Pharmaceuticals, Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Citius Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Cutaneous T-cell Lymphoma Therapies, Anti-infective Solutions, Stem Cell Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Citius Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Citius Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Citius Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.